Non-Hodgkin Lymphoma
From the Journals
Most Cancer Trial Centers Located Closer to White, Affluent Populations
Researchers compare the distributions of patients of different races and socioeconomic statuses to the locations of clinical research facilities...
Commentary
New Drug Approvals Are the Wrong Metric for Cancer Policy
How should we define success in cancer policy — what should the endpoint be?
Feature
Extraordinary Patients Inspired Father of Cancer Immunotherapy
Renowned researcher, Dr. Steven A. Rosenberg, describes his path to pioneering the use of immunotherapies in treating cancer.
From the Journals
Consider These Factors in an Academic Radiation Oncology Position
Editorial gives guidance to radiation oncologists seeking academic positions.
Feature
Look Beyond BMI: Metabolic Factors’ Link to Cancer Explained
A snapshot assessment of metabolic syndrome is inadequate to show an association with cancer risk over time, the authors of new research say.
Feature
ASTRO Pushes Return to Direct Supervision in RT: Needed or ‘Babysitting’?
But some radiation oncologists do not agree with the proposal to move back to direct in-person supervision only.
News
Zanubrutinib Label Expands to Include RR Follicular Lymphoma
The FDA gives expedited approval to zanubrutinib for treating relapsed or refractory cases of the most common type of non-Hodgkin lymphoma.
News from the FDA/CDC
FDA Removes Harmful Chemicals From Food Packaging
The “major source of dietary exposure to PFAS from food packaging” is being eliminated.
Feature
Are Food Emulsifiers Associated With Increased Cancer Risk?
Food emulsifiers are among the most widespread food additives.
Feature
Democratic Lawmakers Press Pfizer on Chemotherapy Drug Shortages
The company, which said in May that it was working to assuage critical shortages of methotrexate, carboplatin and cisplatin, is being asked to...
Commentary
Unleashing Our Immune Response to Quash Cancer
“It’s astounding how devious cancer cells and tumor tissue can be.”